OakChart

Burning Rock Biotech Ltd ADR

BNRHealthcare·Diagnostics & Research·China·Micro·NASD·Nov 11 • 11:16 AM ET

12.68+0.01 (0.08%)
2026-11-11 17:18 CET
Market cap
111.32 USD m
Revenue, TTM
71.59 USD m
Net income, TTM
-9.74 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-0.91
P/E
-
Compare

Price

BNR against its 20, 50 and 200-day averages
2050200
10.0015.0020.00122K245KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BNRclose 12.6820-day 12.3750-day 13.63200-day 15.6312.6852w low

69.6% under the 52-week high of 41.72 on 22 Jan 2026. 52-week low 6.79 on 17 Jun 2026. Last 15 sessions, 44.7% high to low

Profile

BNR
52-week range, 17% of the way up
6.7941.72

Burning Rock Biotech Ltd. engages in the investment of medical fields. It specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. The firm operates through the following segments: Central Laboratory Business, In-Hospital Business and Pharma Research and Development Services. Its products and clinical applications include companion diagnostics for targeted therapy and immunotherapy, benign, malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction and tumor susceptibility tests. The company was founded by Yu Sheng Han in January 2014 and is headquartered in Guangzhou, China.

Employees667
IPOJun 12, 2020
Beta1.50
ATR, 14d1.43
Rel volume0.15
Short float0.39%
Insider own0.24%
Inst own19.81%

Snapshot

6 groups

Valuation

Index-
Market Cap111.46M
Enterprise Value56.34M
Income-9.74M
Sales71.59M
Book/sh6.96
Cash/sh7.03
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees667
IPOJun 12, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S1.56
P/B1.82
P/C1.80
P/FCF-
EV/EBITDA-
EV/Sales0.79
Quick Ratio2.87
Current Ratio3.03
Debt/Eq0.09
LT Debt/Eq0.05
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.91
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y62.63% 40.80%
Sales past 3/5Y-3.55% 3.80%
EPS Y/Y TTM51.30%
Sales Y/Y TTM-3.65%
EPS Q/Q-99.84%
Sales Q/Q-3.60%
EarningsSep 10 BMO
EPS/Sales Surpr.- -

Ownership

Insider Own0.24%
Insider Trans-
Inst Own19.81%
Inst Trans-1.15%
ROA-8.63%
ROE-12.81%
ROIC-12.69%
Gross Margin74.52%
Oper. Margin-13.02%
Profit Margin-13.60%
SMA202.47%
SMA50-6.94%
SMA200-18.88%
Trades-

Technical

Shs Outstand8.79M
Shs Float8.76M
Short Float0.39%
Short Ratio0.99
Short Interest0.03M
52W High41.72 -69.61%
52W Low6.79 86.75%
Volatility12.19% 13.12%
ATR (14)1.43
RSI (14)49.11
Beta1.50
Rel Volume0.15
Avg Volume34.86K
Volume1,613

Performance

Perf Week-1.17%
Perf Month-15.47%
Perf Quarter36.49%
Perf Half Y-24.34%
Perf YTD-37.07%
Perf Year6.20%
Perf 3Y25.54%
Perf 5Y-91.22%
Perf 10Y-
Recom-
Target Price31.65
Prev Close12.67
Price12.68
Change %0.08%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Oct 15, 2021ResumedCCowenOutperform
Jul 07, 2020InitiatedCCowenOutperform

Peers

Mkt cap
TickerCompanyMkt cap
GHGuardant Health Inc21.51B
GRALGRAIL Inc5.85B
NEONeogenomics Inc2.22B
PSNLPersonalis Inc1.73B
FLGTFulgent Genetics Inc740.22M
NTRANatera Inc46.56B
MYGNMyriad Genetics Inc554.49M
CSTLCastle Biosciences Inc1.07B
BDSXBiodesix Inc123.53M
TEMTempus AI Inc15.05B

Insider trading

8 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Han YushengDirectorJun 24 '26Buy8.00250,0002,000,00018,379,186Jul 02 08:30 AM
Han YushengDirectorJun 12 '26Buy9.25210,0001,942,14317,907,436Jul 02 08:30 AM
Han YushengDirectorJun 16 '26Buy9.00111,110999,95718,018,546Jul 02 08:30 AM
Han YushengDirectorJun 22 '26Buy7.45104,650779,67418,123,196Jul 02 08:30 AM
Han YushengDirectorJun 11 '26Buy8.7424,760216,38817,697,436Jul 02 08:30 AM
Han YushengDirectorJun 26 '26Buy8.0024,900199,09018,404,086Jul 02 08:30 AM
Han YushengDirectorJun 23 '26Buy7.505,99044,92018,129,186Jul 02 08:30 AM
Han YushengDirectorMar 31 '26Buy17.36314,8705,466,14317,672,676Apr 02 07:17 AM

Held by

AUM
TickerCompanyAUM
BAIVBrown Advisory International Value Select ETFAUM: 196.86M

News

latest 14 of 103
  • Burning Rock Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • Burning Rock Announces Founder's Purchase of Its ADSs (GlobeNewswire) +9.60%
  • Burning Rock Reports First Quarter 2026 Financial Results (GlobeNewswire) -9.81%
  • Burning Rock Publishes 2025 Annual Report on Form 20-F (GlobeNewswire) -12.64%
  • Burning Rock Announces Founder's Purchase of Its ADSs (GlobeNewswire)
  • Loading…
  • Burning Rock Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
  • Burning Rock Announces Founder's Purchase of Its ADSs (GlobeNewswire) +24.39%
  • Burning Rock Announces Results of 2025 Annual General Meeting (GlobeNewswire) +7.79% -6.93%
  • Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025 (GlobeNewswire) -12.04%
  • This Undiscovered Biotech Stock Has Quintupled in a Year and Just Hit New Highs (Barchart) +9.72%
  • Burning Rock Reports Third Quarter 2025 Financial Results (GlobeNewswire)
  • Burning Rock's OncoGuide OncoScreen Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer (GlobeNewswire)
  • Burning Rock Reports Second Quarter 2025 Financial Results (GlobeNewswire) +9.16%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2024Q32024-12-04-0.048--17.66--
2024Q22024-08-23-0.147--1.45418.97--
2024Q12024-05-29-0.250--1.64919.67--
2023Q42024-03-28-21.862--2.19116.75--
2023Q32023-11-30-2.415--2.36018.01--
2023Q22023-08-31-1.757-1.913-1.82620.08-1
2023Q12023-05-30-2.559-2.012-2.64420.15-1
2022Q42023-03-28-3.066-3.352-2.96820.6716.512
2022Q32022-11-16-3.165-2.637-3.25221.9522.092
2022Q22022-08-31-3.617-2.750-3.78518.9322.602
2022Q12022-05-31-3.752-2.815-3.94020.3421.772
2021Q42022-03-22-3.775-2.357-3.76123.1821.452
2021Q32021-11-16-2.569-2.517-2.52819.8420.171
2021Q22021-08-31-3.030-2.319-3.02919.6821.632
2021Q12021-05-25-2.568-2.305-2.54310.4819.35-
2020Q42021-03-11-15.100-12.400-2.274131.72125.1-

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-10.597-6.395-9.96266.2265.00
2021FY-12.028-10.991-11.85479.8578.90
2022FY-13.580--13.88181.80-
2023FY-8.827--74.36-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2024FYS2023-09-20100112.1112.1112.1
2024FYS2023-09-19100112.1112.1112.1
2024FYS2023-09-18100112.1112.1112.1
2024FYS2023-09-17100112.1112.1112.1
2024FYS2023-09-16100112.1112.1112.1
2024FYS2023-09-13100112.1112.1112.1
2024FYS2023-09-12100112.1112.1112.1
2024FYS2023-09-11100112.1112.1112.1
2024FYS2023-09-10100112.1112.1112.1
2024FYS2023-09-09100112.1112.1112.1
2024FYS2023-09-06100112.1112.1112.1
2024FYS2023-09-05100112.1112.1112.1
2024FYS2023-09-04100112.1112.1112.1
2024FYS2023-09-03100112.1112.1112.1

Estimate history

EPS, annual-2.631-3.383-4.659-9.962-11.854-13.881-9.011-4.679-0.724-0.9125
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.454-0.483-1.094-0.172-0.125-0.217-0.206-0.24-0.249
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual16.44931.56555.23762.28578.74683.64475.85571.67475.0671.59
Period201720182019202020212022202320242025TTM
Sales, quarterly18.71517.94817.52918.28920.53718.38917.81515.58919.798
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual8.6488.6488.6488.7468.7788.5328.5129.0298.7868.786
Period201720182019202020212022202320242025MRQ
Shares, quarterly8.5128.2339.0299.0349.0349.0348.7868.7868.786
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue71.5975.0671.6775.8683.6478.7562.2855.2431.57
Cost of Goods Sold Incl. D&A18.2419.0121.3224.5927.2122.2816.8015.6811.15
Gross Profit53.3556.0550.3651.2756.4456.4645.4839.5620.41
Selling, General and Administrative Excl. Other62.6663.6895.16145.74202.04180.05105.2364.0344.80
Research and Development19.2823.1632.2848.9862.6557.0438.2422.7115.91
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-9.32-7.63-44.80-94.47-145.60-123.59-59.75-24.47-24.39
Interest Expense0.010.000.00--0.240.10-2.51
Unusual Expense0.000.004.880.000.000.00-0.510.410.00
Net Income Before Taxes-9.51-7.48-47.35-91.93-143.94-123.39-59.00-24.48-26.82
Income Taxes0.230.220.820.340.290.140.000.000.00
Consolidated Net Income-9.74-7.70-48.16-92.26-144.23-123.53-59.00-24.48-26.82
Net Income From Continuing Operations-9.74-7.70-48.16-92.26-144.23-123.53-59.00-24.48-26.82
Net Income-9.74-7.70-48.16-92.26-144.23-123.53-68.37-48.36-35.11
EPS (Recurring)-0.90-0.72-4.35-9.01-13.88-11.85-10.01-4.63-3.38
EPS (Basic, Before Extraordinaries)-0.91-0.72-4.68-9.01-13.88-11.85-9.96-4.66-3.38
EPS (Diluted)-0.91-0.72-4.68-9.01-13.88-11.85-9.96-4.66-3.38
EBITDA-6.35-4.60-37.55-75.64-127.17-116.18-54.92-19.93-20.66
Non-Operating Income (Expense)-0.180.152.342.541.660.430.340.400.08
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.151.4516.2227.6036.4032.8425.102.470.58
Price To Sales Ratio1.272.850.971.262.8012.6125.46--
Gross Margin74.5274.6770.2667.5967.4771.7073.0271.6164.66
Operating Margin-13.02-10.16-62.51-124.54-174.07-156.94-95.93-44.30-77.27
Net Margin-13.60-10.26-67.20-121.63-172.44-156.87-109.77-87.55-111.24
Shares Outstanding8.798.799.038.518.538.788.758.658.65
Market Capitalization111.32111.3255.5779.35197.69836.582,020.262,014.98-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue19.8015.5917.8118.3920.5418.2917.5317.95
Cost of Goods Sold Incl. D&A5.434.323.914.585.594.905.095.13
Gross Profit14.3711.2713.9013.8114.9513.3912.4412.81
Selling, General and Administrative Excl. Other17.0113.9915.6016.0616.5315.4718.9518.20
Research and Development4.593.984.925.796.885.557.266.86
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.64-2.72-1.70-2.25-1.59-2.09-6.51-5.38
Interest Expense0.000.000.000.00-0.000.000.00
Unusual Expense0.000.000.000.000.000.004.890.00
Net Income Before Taxes-2.66-2.49-2.05-2.31-1.31-1.82-10.57-4.96
Income Taxes0.040.030.120.030.030.030.740.03
Consolidated Net Income-2.70-2.52-2.17-2.34-1.34-1.86-11.31-4.99
Net Income From Continuing Operations-2.70-2.52-2.17-2.34-1.34-1.86-11.31-4.99
Net Income-2.70-2.52-2.17-2.34-1.34-1.86-11.31-4.99
EPS (Recurring)-0.25-0.24-0.21-0.22-0.12-0.17-0.76-0.48
EPS (Basic, Before Extraordinaries)-0.25-0.24-0.21-0.22-0.12-0.17-1.09-0.48
EPS (Diluted)-0.25-0.24-0.21-0.22-0.12-0.17-1.09-0.48
EBITDA-2.31-2.360.28-1.96-1.26-1.64-1.99-4.56
Non-Operating Income (Expense)-0.020.23-0.35-0.060.280.260.830.42
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.220.200.330.400.330.470.841.06
Price To Sales Ratio1.272.352.821.250.460.670.970.48
Gross Margin72.5872.2778.0375.1072.7773.1970.9671.40
Operating Margin-13.36-17.46-9.53-12.26-7.74-11.41-37.14-30.00
Net Margin-13.66-16.19-12.18-12.73-6.53-10.14-64.51-27.79
Shares Outstanding8.798.798.799.039.039.039.038.23
Market Capitalization111.32145.72182.0478.1628.5337.0555.5727.79

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments68.8471.5486.75133.10235.81349.7659.1819.24-
Short Term Receivables27.5823.7623.6624.4925.6222.5029.9412.01-
Inventories6.958.589.7318.7519.3310.408.347.14-
Other Current Assets1.112.524.524.744.953.232.614.28-
Total Current Assets104.49106.40124.66181.07285.71385.89100.0842.67-
Net Property, Plant & Equipment10.5713.7520.3343.1663.7717.0512.8210.13-
Total Investments and Advances0.000.000.050.100.140.225.770.29-
Long-Term Note Receivable-0.000.750.73-----
Intangible Assets0.040.060.140.290.810.530.050.07-
Other Assets2.291.090.723.017.083.522.961.11-
Total Assets117.40121.29146.64228.36357.52407.20121.6854.28-
Short Term Debt Incl. Current Port. of LT Debt2.433.371.225.365.867.176.3726.06-
Accounts Payable5.834.622.557.339.905.431.772.37-
Other Current Liabilities27.0828.4933.3746.5042.6424.3415.4613.03-
Total Current Liabilities35.3436.4837.1359.1958.4036.9323.6141.47-
Long Term Debt3.743.800.521.957.740.003.3113.59-
Provision for Risks Charges0.000.000.000.000.000.003.370.00-
Other Liabilities1.711.430.640.591.850.030.000.00-
Total Liabilities40.8041.7138.2961.7367.9836.9730.3055.06-
Non-Equity Reserves0.000.000.000.000.000.040.140.29-
Preferred Stock - Carrying Value0.000.000.000.000.000.00219.2286.83-
Common Equity76.6079.57108.35166.63289.54370.20-127.98-87.90-
Total Shareholders Equity76.6079.57108.35166.63289.54370.2091.24-1.07-
Accumulated Minority Interest0.000.000.000.000.000.000.000.00-
Total Equity76.6079.57108.35166.63289.54370.2091.24-1.07-
Total Liabilities & Stockholders Equity117.40121.29146.64228.36357.52407.20121.6854.28-
Book Value Per Share7.287.3910.5816.2327.5535.33-12.33-8.47-
Tangible Book Value Per Share8.718.8112.7119.5032.8942.27-14.80-10.17-
Full-Time Employees6676747861,1381,394938705528-
Price to Book Ratio1.820.600.811.293.466.546.50--
Return on Assets-6.45-35.95-49.21-49.24-32.31-22.31-27.83--
Return on Equity-9.86-51.26-67.11-63.24-37.45-25.57-54.30--
Return on Invested Capital-9.58-57.77-84.75-85.56-41.55-15.94-25.89-214.18-
Quick Ratio2.762.683.092.744.5610.173.890.86-
Current Ratio2.962.923.363.064.8910.454.241.03-

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income--7.70-48.16-92.26-144.23-123.53-59.00-24.48-26.82
Depreciation-3.037.2518.8318.437.414.834.543.73
Other Funds (Non Cash)-8.9833.1744.6959.6251.7027.285.821.54
Funds from Operations-4.30-7.74-28.74-66.18-64.42-26.90-14.12-21.55
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital--8.26-5.08-7.36-1.66-9.6716.24-18.88-0.93
Cash from Operating Activities-2.13-3.96-12.82-36.10-67.84-74.10-10.65-33.00-22.48
Capital Expenditures--0.73-0.83-1.32-10.47-33.10-11.52-6.62-3.74
Net Assets From Acquisitions-0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.120.220.010.360.090.090.010.02
Purchase or Sale of Investments-0.000.000.009.7445.68-4.41-43.5619.75
Purchase of Investments-0.000.000.000.00-9.91-50.48-59.140.00
Sale Or Maturity of Investments-0.000.000.009.7455.5946.0715.5719.75
Other Uses-0.000.000.00-0.740.000.000.000.00
Other Sources-0.00-0.000.000.000.000.000.00
Cash from Investing Activities-0.84-0.61-0.61-1.31-1.1112.67-15.84-50.1716.03
Cash Dividends Paid-0.000.000.000.000.000.000.000.00
Change in Capital Stock-0.00-0.01-0.98-10.67-0.66316.7594.550.08
Repurchase of Common Pref Stock-0.00-0.01-0.98-10.67-0.66-0.51-0.60-0.23
Sale of Common Pref Stock-0.000.000.000.000.00317.2695.150.30
Proceedsfrom Stock Options-0.000.000.000.000.00278.150.000.00
Issuance or Reduction of Debt, Net-0.260.00--0.35-6.95-2.98-11.8112.53
Change in Long Term Debt-0.260.00-0.00-6.17-3.71-10.4613.37
Issuance of Long Term Debt-0.280.00-0.000.002.642.1314.60
Reduction of Long Term Debt--0.010.00-0.00-6.17-6.35-12.59-1.23
Net Financing Active Other Cash Flow-0.000.00-5.91-1.79-0.590.000.000.00
Other Financing Activities Uses-0.000.00-5.91-1.79-0.590.000.000.00
Cash from Financing Activities-0.030.26-0.01-6.89-12.81-8.20313.7782.7412.60
Exchange Rate Effect-2.49-1.410.510.555.45-5.74-22.590.85-0.02
Net Change in Cash-5.49-5.71-12.93-43.76-76.31-75.37264.690.426.13
Free Cash Flow--4.69-13.57-37.25-78.28-106.80-21.60-39.56-26.20
Preferred Dividends (Cash Flow)-0.000.000.000.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments61.7764.9668.8465.6063.5068.59
Short Term Receivables26.9025.6527.5827.6628.5724.36
Inventories5.037.866.957.658.079.02
Other Current Assets3.343.001.112.953.253.04
Total Current Assets97.03101.47104.49103.86103.39105.02
Net Property, Plant & Equipment11.5111.4310.579.2810.7611.72
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.030.040.040.040.050.05
Other Assets2.041.102.290.910.931.08
Total Assets110.62114.04117.40114.09115.13117.86
Short Term Debt Incl. Current Port. of LT Debt3.153.092.432.362.723.11
Accounts Payable2.652.615.834.824.494.96
Other Current Liabilities26.2727.5727.0825.8524.9126.75
Total Current Liabilities32.0633.2735.3433.0332.1234.81
Long Term Debt3.504.283.742.302.752.73
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities1.811.731.711.561.521.47
Total Liabilities37.3639.2840.8036.8936.3839.01
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity73.2674.7676.6077.2078.7478.85
Total Shareholders Equity73.2674.7676.6077.2078.7478.85
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity73.2674.7676.6077.2078.7478.85
Total Liabilities & Stockholders Equity110.62114.04117.40114.09115.13117.86
Book Value Per Share6.967.117.287.177.317.32
Tangible Book Value Per Share8.338.508.718.548.718.72
Full-Time Employees--667---
Price to Book Ratio1.822.252.811.180.430.40
Return on Assets-8.63-7.22-6.46-13.24-15.23-26.02
Return on Equity-12.81-10.91-9.87-19.87-22.66-37.15
Return on Invested Capital-3.52-3.19-2.70-2.94-1.65-2.27
Quick Ratio2.872.812.762.912.972.76
Current Ratio3.033.052.963.143.223.02

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash from Operating Activities-3.30-4.233.182.21-6.12-3.23
Cash from Investing Activities-0.36-0.05-0.05-0.380.03-0.21
Cash Dividends Paid----0.000.00
Preferred Dividends (Cash Flow)----0.000.00
Change in Capital Stock----0.000.00
Sale of Common Pref Stock----0.000.00
Proceedsfrom Stock Options----0.000.00
Issuance or Reduction of Debt, Net----0.000.00
Change in Long Term Debt----0.000.00
Issuance of Long Term Debt----0.000.00
Reduction of Long Term Debt----0.000.00
Net Financing Active Other Cash Flow----0.000.00
Other Financing Activities Uses----0.000.00
Cash from Financing Activities-0.010.00-0.010.000.280.00
Exchange Rate Effect-0.69-0.39-1.18-0.23-0.030.04
Net Change in Cash-4.36-4.671.941.60-5.85-3.40

Revenue breakdown

Product2024: 31.32M 2025: 31.09M
Service2024: 40.46M 2025: 43.99M
China2024: 71.00M 2025: 75.08M
United States2024: 776.58K
Central laboratory business2024: 24.44M 2025: 22.26M
Inhospital business2024: 31.24M 2025: 31.17M
Pharma research and development services2024: 16.10M 2025: 21.64M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.39%0.0M8.8M32.17K
2026-10-150.42%0.0M8.8M29.27K
2026-09-300.47%0.0M8.8M29.75K
2026-09-150.45%0.0M8.8M27.28K
2026-08-310.44%0.0M8.8M17.08K
2026-08-140.45%0.0M8.8M19.48K
2026-07-310.45%0.0M8.8M19.76K
2026-07-150.51%0.0M8.8M24.74K
2026-06-300.40%0.0M8.8M24.49K
2026-06-150.37%0.0M8.8M26.97K
2026-05-290.41%0.0M8.8M26.60K
2026-05-150.53%0.0M8.8M27.18K
2026-04-300.54%0.0M8.8M27.58K
2026-04-150.53%0.0M9.0M25.88K
2026-03-310.71%0.1M9.0M28.51K
2026-03-130.73%0.1M9.0M31.70K
2026-02-270.81%0.1M9.0M38.14K
2026-02-130.85%0.1M9.0M46.47K
2026-01-300.79%0.1M9.0M48.84K
2026-01-150.68%0.1M9.0M50.85K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-10SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-09SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-13SCHEDULE 13G/ASEC
2026-04-2820-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-04-024Statement of changes in beneficial ownership of securities2026-03-31SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-173Initial statement of beneficial ownership of securities2026-03-17SEC
2026-03-173Initial statement of beneficial ownership of securities2026-03-17SEC
2026-03-173Initial statement of beneficial ownership of securities2026-03-17SEC
2026-03-173Initial statement of beneficial ownership of securities2026-03-17SEC
2026-03-173Initial statement of beneficial ownership of securities2026-03-17SEC
2026-03-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-12SEC
2025-12-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-23SEC
2025-12-19SCHEDULE 13GSEC
2025-12-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-01SEC
2025-11-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-11-20SEC
2025-11-14SCHEDULE 13G/ASEC
2025-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-09-08SEC
2025-06-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-06-06SEC
2025-04-2920-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2024-12-31SEC
2025-03-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-03-25SEC
2024-12-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162024-12-31SEC
2024-12-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162024-12-04SEC
2024-12-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162024-12-03SEC
2024-11-27UPLOADUpload SubmissionSEC
2024-11-26CORRESPSEC
2024-11-2620-F/A2023-12-31SEC
2024-11-14SC 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-066.18M700
2026-050000
2026-040000
2026-035.47M100
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Kynam Capital Management, LP14.10%
CRCM LP4.83%
RENAISSANCE TECHNOLOGIES LLC0.60%
MORGAN STANLEY0.50%
Sumitomo Mitsui Trust Group, Inc.0.34%
Amova Asset Management Americas, Inc.0.34%
BANK OF AMERICA CORP /DE/0.33%
CITADEL ADVISORS LLC0.31%
HSG Holding Ltd0.24%
UBS Group AG0.20%

Funds

Fund% owned
AMG Yacktman Focused Fund6.26%
AMG Yacktman Fund5.69%
Brown Advisory - WMC Strategic European Equity Fund3.59%
Old Westbury Small & Mid Cap Strategies Fund1.27%
Goldman Sachs ActiveBeta(R) International Equity ETF0.93%
Avantis International Equity ETF0.91%
Xtrackers MSCI EAFE High Dividend Yield Equity ETF0.73%
Xtrackers MSCI EAFE Hedged Equity ETF0.54%
First Trust Germany AlphaDEX Fund0.32%
Wilmington International Fund0.30%

OakChart. BNR. Cached 15 minutes.